UroGen Pharma Ltd. (URGN) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for UroGen Pharma Ltd. (URGN): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 60/100 — a percentile rank of UroGen Pharma Ltd.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.
| Market cap | $2.0B |
| P / S | 10.7× |
| EV / EBITDA | -32.2× |
| Gross margin | 90.8% |
| Operating margin | -35.3% |
| Net margin | -51.7% |
| Return on equity | 73.8% |
| ROIC | 359.6% |
| Revenue growth | 100.3% |
| Debt / equity | -1.5× |
| Dividend yield | 0.0% |
Is UroGen Pharma Ltd. overvalued? P/S looks overvalued vs its 5-year range.
Independent of the events above — derived from UroGen Pharma Ltd.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact